RSCM
OCUL icon

Rock Springs Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Rock Springs Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
383,716
+37,896
+11% +$361K 0.19% 76
2025
Q4 		$4.2M Buy
345,820
+45,820
+15% +$557K 0.22% 76
2025
Q3 		$3.51M Buy
+300,000
New +$3.59M 0.2% 70

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Rock Springs Capital Management's OCUL Position: Q1 2026 in Review

Rock Springs Capital Management increased its Ocular Therapeutix (OCUL) stake by 11% in Q1 2026, buying an estimated $361K and bringing the position to 383,716 shares worth $3.25M. The position accounts for 0.19% of the portfolio, ranked #76.

Rock Springs Capital Management first reported a position in OCUL in Q3 2025 and has held it in 3 quarters since. The position peaked at $4.2M in Q4 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Rock Springs Capital Management held 383,716 shares of Ocular Therapeutix worth $3.25M as of Q1 2026.
  • Rock Springs Capital Management bought 37,896 Ocular Therapeutix shares in Q1 2026, an estimated $361K.
  • Ocular Therapeutix made up 0.19% of Rock Springs Capital Management's portfolio in Q1 2026, its #76 holding.
  • Rock Springs Capital Management first reported a position in Ocular Therapeutix in Q3 2025 and has held it in 3 quarters since.
  • Rock Springs Capital Management's Ocular Therapeutix position peaked at $4.2M in Q4 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Rock Springs Capital Management's 13F filing for Q1 2026, filed 15 May 2026.